Dashboard
Manage Tickers

SGMT


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

sagimet-biosciences-announces-denifanstat-achieved-all-primary-and-secondary-endpoints-and-was-generally-well-tolerated-in-phase-3-clinical-trial-in-acne-in-china
Sagimet Biosciences Announces Denifanstat ...
10/24/2025 11:05:12

this-visa-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Visa Analyst Begins Coverage On A Bul...
10/22/2025 13:31:46

clear-street-initiates-coverage-on-sagimet-biosciences-with-buy-rating-announces-price-target-of-29
Clear Street Initiates Coverage On Sagimet...
10/22/2025 11:14:25

Clear Street analyst Kaveri Pohlman initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announces ...

sagimet-biosciences-to-showcase-fascinate-2-study-results-on-denifanstats-fibrosis-improvement-in-advanced-mash-at-liver-meeting-2025
Sagimet Biosciences To Showcase FASCINATE-...
10/07/2025 11:14:40

canaccord-genuity-maintains-buy-on-sagimet-biosciences-maintains-28-price-target
Canaccord Genuity Maintains Buy on Sagimet...
10/02/2025 12:25:40

Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $28 price target.

sagimet-doses-first-participants-in-phase-1-pharmacokinetic-trial-of-combination-of-oral-once-daily-fasn-inhibitor-denifanstat-and-thr--agonist-resmetirom-topline-data-expected-in-h1-2026
Sagimet Doses First Participants In Phase ...
10/01/2025 11:17:45

Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, ...

sagimet-confirms-phase-3-denifanstat-success-in-moderate-to-severe-acne-with-eadv-2025-oral-presentation-in-paris-scheduled
Sagimet Confirms Phase 3 Denifanstat Succe...
09/17/2025 11:16:39

Denifanstat met all primary and secondary endpoints versus placeboDenifanstat was generally well toleratedSagimet initiated fir...

sagimet-to-present-new-mash-research-and-join-drug-development-panel-at-boston-summit
Sagimet To Present New MASH Research And J...
09/10/2025 11:10:35

Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targ...

sagimet-biosciences-enters-sales-agreement-with-leerink-partners-may-offer-shares-up-to-75m
Sagimet Biosciences Enters Sales Agreement...
08/14/2025 21:54:32

-SEC Filing

sagimet-biosciences-q2-eps-032-beats-053-estimate
Sagimet Biosciences Q2 EPS $(0.32) Beats $...
08/13/2025 11:35:26

Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $...

wedbush-initiates-coverage-on-sagimet-biosciences-with-outperform-rating-announces-price-target-of-28
Wedbush Initiates Coverage On Sagimet Bios...
08/11/2025 11:56:58

Wedbush analyst Yun Zhong initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Outperform rating and announces Pri...

hc-wainwright--co-assumes-sagimet-biosciences-at-buy-announces-price-target-of-29
HC Wainwright & Co. Assumes Sagimet Biosci...
08/07/2025 11:14:12

HC Wainwright & Co. analyst Brandon Folkes assumes Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announces Pri...

this-sarepta-therapeutics-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-thursday
This Sarepta Therapeutics Analyst Begins C...
07/24/2025 12:46:26

canaccord-genuity-initiates-coverage-on-sagimet-biosciences-with-buy-rating-announces-price-target-of-28
Canaccord Genuity Initiates Coverage On Sa...
07/24/2025 10:19:52

Canaccord Genuity analyst Edward Nash initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announce...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
06/12/2025 17:06:14

sagimets-partner-achieves-positive-results-with-oral-acne-drug-in-phase-3-trial-in-china-stock-jumps
Sagimet's Partner Achieves Positive Result...
06/04/2025 12:28:11

Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a secon...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/04/2025 12:08:36

sagimet-biosciences-reported-denifanstat-met-all-primary-and-secondary-endpoints-in-a-phase-3-clinical-trial-for-the-treatment-of-moderate-to-severe-acne-vulgaris-conducted-by-sagimets-license-partner-ascletis-bioscience-co-ltd-ascletis-in-china
Sagimet Biosciences Reported Denifanstat M...
06/04/2025 09:03:09

reported-earlier-ascletis-denifanstat-licensed-from-sagimet-meets-all-endpoints-in-phase-iii-trial-for-moderate-to-severe-acne
Reported Earlier, Ascletis' Denifanstat, L...
06/04/2025 06:36:03

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated statistically significant and clinica...

sagimet-biosciences-q1-2025-eps-056-beats-065-estimate-cash-cash-equivalents-and-marketable-securities-as-of-march-31-2025-were-1446m
Sagimet Biosciences Q1 2025 EPS $(0.56) Be...
05/08/2025 10:14:24

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION